Klinikum Hochsauerland GmbH — Clinical Trial Site

7 Registered trials

5 Currently recruiting

Organisation

Klinikum Hochsauerland GmbH

Location

Meschede, Germany

Identifier

ORG-100033640

Address

Schederweg 12, 59870, Germany

Departments

Hämatologie, Onkologie, Pallativmedizin und Stammzelltransplantation
Hämatologie, Onkologie, Palliativmedizin und Stammzelltransplantation Meschede
Klinik f. Hämatologie, Onkologie, Palliativmedizin, Stammzelltransplantation
Klinik für Hämatologie, Onkologie, Palliativmedizin und Stammzelltransplantation
Klinik für Hämatologie• Onkologie• Palliativmedizin• Stammzelltransplantation

Clinical trials at this site (7)

Search interface

A randomized phase III trial assessing iberdomide versus iberdomide plus isatuximab maintenance therapy post autologous hematopoietic stem-c… Recruiting

2023-507402-13-00 Multiple myeloma 5 2024-04-03
A Randomized, Placebo‐Controlled Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Adult Patients With Newly Di… Recruiting

2023-507518-28-00 Acute myeloid leukemia 5 2022-09-13
A PROSPECTIVE, OPEN-LABEL, MULTICENTER, RANDOMIZED, PHASE 3 TRIAL OF ACALABRUTINIB, OBINUTUZUMAB AND VENETOCLAX (GAVE) COMPARED TO OBINUTUZU… Recruiting

2023-506414-46-00 High risk patients defined as having at least one of th 5 2022-04-22
Pre-Operative Treatment in rEseCTable cOlon canceR (PROTECTOR/FIRE-10; AIO-KRK-0620; IAG-VO-0323) Prospective, randomized, open-label, multi… Recruiting

2023-508076-11-00 Colon cancer staged T3-4 and/or nodal positive by CT an 5 2025-04-01
A multicentre, randomized trial in adults with de novo Philadelphia-Chromosome positive acute lymphoblastic leukemia to assess the efficacy … Recruiting

2024-517966-40-00 Acute lymphoblastic leukemia (ALL), de novo, Ph/BCR::AB 4 2023-07-13
A phase II, open-label, single arm study to evaluate the efficacy of Luspatercept in Erythropoiesis-stimulating agent naive lower-risk MDS p… Ended

2024-516438-36-00 Patients with very low, low or intermediate risk myelod 4 2022-09-13
A randomized phase III non-inferiority trial assessing lenalidomide, bortezomib and dexame-thasone induction therapy with either intravenous… Ended

2024-516300-41-00 Multiple Myeloma 5 2023-03-07